We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 30.68+1.7%Jun 5 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fitzhughlaw who wrote (52460)9/11/2019 8:15:30 PM
From: idahoranch17 Recommendations

Recommended By

and 2 more members

   of 56638
I had this conversation with Chau a couple of months ago. He said that until EV had full approval with their phase lll trial, irrespective of AA, 132 has a clear runway to AA. Once getting AA, it doesn’t matter if EV gets full phase lll approval, 132, buy virtue of AA, would get it’s review out of the phase lll trial and could be approved by meeting it’s primary endpoints. BTD simply greases the path somewhat, but has no bearing on approvals.

If EV got full approval through the phase lll trial before 132 got AA, then 132’s trial end points for AA or approval wouldn’t be valid.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext